Biotech News
Related news
OTLKOutlook2026-04-21 13:05 EST
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
OTLKOutlook2026-04-07 12:50 EST
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
LENZLenz Therapeutics Inc2026-06-07 23:30 EST
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
OCSOculis2026-08-03 08:00 EST
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
OKYOOKYO Pharma2026-07-08 11:00 EST
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
TARSTarsus Pharmaceuticals2026-03-23 12:30 EST
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
SGHTSight Sciences2026-08-04 21:38 EST
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
MGTXMeiraGTx2026-07-07 11:30 EST
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
MGTXMeiraGTx2026-03-26 12:01 EST
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
HROWHarrow, Inc.2026-08-06 11:00 EST
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Outlook
Outlook Therapeutics is an ophthalmology company focused on retinal disease and anti-VEGF therapy delivery. Its story centers on whether it can create a differentiated eye-care franchise.
Recent company news
OTLKOutlook2026-08-06 12:45 EST
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
OTLKOutlook2026-07-24 18:40 EST
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
OTLKOutlook2026-06-16 12:02 EST
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
OTLKOutlook2026-06-01 12:46 EST
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
OTLKOutlook2026-05-28 20:00 EST
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Stock data
- Close
- 0.97 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States